Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. He holds an academic appointment of Clinical Associate Professor at the University of Sydney. He is Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.
He graduated from University of Sydney Medical School, underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.
His commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) and the RANZCO Excellence in Teaching Award.
Associate Professor Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical and Experimental Ophthalmology.
In wider healthcare activities, Associate Professor Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.
Chow N, Hong T, Chang A. Multimodal imaging of macular subretinal deposits following intravitreal ocriplasmin injection. AJO Case Reports 2018 [Epub ahead of print]
Spooner K, Bahrami B, Hong T, Chang A. A Meta-Analysis of Patients with Treatment Resistant Macular Oedema Secondary to Retinal Vein Occlusions following Switching to Aflibercept. Acta Ophthalmologica (Accepted for publication)
Bahrami B, Hong T, Schlub T, Chang A. Aflibercept for persistent diabetic macular edema: 48 week outcomes. Retina. (in press)
Ong PC, Te NA, Zagora S, Symes R, Yates Y, Chang A, McCluskey P, Simunovic M. Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora. Clinical & Experimental Ophthalmology (In press)
Chang A, Chan P, Schlottman. Latest developments in age-related macular degeneration. Asia Pac J Ophthalmol. 2017 [Epub ahead of print]
Bahrami B, Hong T, Gilles MC, Chang A. Anti-VEGF therapy for diabetic eye disease. Asia Pac J Ophthalmol (Phila). 2017 Oct 26. doi: 10.22608/APO.2017350. [Epub ahead of print]
Broadhead G, Hong T, Grigg J, McCluskey P, Schlub T, Chang A. Choroidal Thickness and Microperimetry Sensitivity in Age-Related Macular Degeneration. Ophthalmic Research (Accepted for publication)
Bahrami B, Hong T, Zhu M, Schlub T, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. (Accepted for publication)
Chew J, Zhu M, Broadhead G, Luo K, Hong T, Chang A. Bilateral neovascular age-related macular degeneration: Comparisons between first and second eyes. Ophthalmologica (Accepted for publication)
Bahrami B, Ewe S, Hong T, Zhu M, Ong G, Luo K, Chang A. Influence of retinal pathology on the reliability of macular thickness measurement: a comparison between optical coherence tomography devices. Ophthalmic Surgery Laser and Imaging Retina. (Accepted for publication)
Nair R, Chang A. Challenges in the treatment of age-related macular degeneration. Medicine Today. 2017, 18(2): 400-400
Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clinical Ophthalmology 2017, 11:161-177
Bahrami B, Hong T, Zhu M, Schlub TE, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140
Zhu M, Wijeyakumar W, Syed A, Joachim N, Hong T, Broadhead G, Li H, Luo K, Chang A, Vision-related quality of life: 12 month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2016, [epub]
Powner M, Sim D, Zhu M, Nobre-Cardoso J, Jones R, Syed A, Chang A , Keane P, Tufail A, Egan C. Evaluation of non-perfused retinal vessels in ischemic retinopathy. IOVS 2016, 1:57 (11) 5031-5037
Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 2016, 59(8): 1594-608
G K Broadhead, JR Grigg, P McCluskey, M Korsakova, AA Chang. Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome. Documenta Ophthalmologica 2016; 133(2): 139-143
Chang A, Broadhead G, Hong T, Joachim N, Syed A, Schlub T, Toth L, Peto T, Zhu M. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes. Opthalmic Research 2016; 55: 84-9
Ewe S, Jamieson R, Chang A. Masquerade macular exudation in Mallatia Leventinese. Can J Ophthalmol 2016; 51: e24–e27
Chang A, Li H, Broadhead G, Luo K, Zhu M, Safety and Efficacy of Intravitreal Preservative-free Triamcinolone Acetonide (Triesence) for Macular Edema. Journal of Ocular Pharmacology and Therapeutics. 2015:31(9):563-9
Chang AA, Hong T, Ewe S, Badami B. The Role of Aflibercept in the management of Diabetic Macular Edema. Drug Design, Development and Therapy. 2015, 6:9:4389-96
Broadhead GK, Chang AA. Intravitreal aflibercept for choroidal neovascularization complicating chronic central serous retinopathy. Graefes Archive for clinical and experimental ophthalmology.
Broadhead GK, Grigg J, Chang AA, McCluskey P. Dietary Modification and Supplementation for the Treatment of Age-Related Macular Degeneration. Nutrition Reviews 2014.
Staffieri SE, Rose L, Chang A, De Roach JN, McLaren TL, Mackey DA, Hewitt AW, Lamey TM. Clinical and molecular characterisation of females affected by X-linked retinoschisis. Clinical Experimental Ophthalmology 2015, 43(7):643-7
Broadhead GK, T Hong, Zhu M, Schulb T, Wijeyakumar W, Chang AA. Response of Pigment Epithelial Detachments to Intravitreal Aflibercept among Patients with Treatment-Resistant Neovascular Age-Related Macular Degeneration. Retina, 2015; 35(5): 975-81
Broadhead GK, T Hong, Zhu M, Schulb T, Wijeyakumar W, Chang AA. Response of Pigment Epithelial Detachments to Intravitreal Aflibercept Among Patients with Treatment-Resistant Neovascular Age-Related Macular Degeneration. Retina, 2014.
Zhu M, Chew J, Broadhead G, Luo K, Joachim N, Hong T, Syed A, Chang AA. Intravitreal Ranibizumab for neovascular age-related macular degeneration in clinical practice: 5 year treatment outcomes. Graefes Archive for clinical and experimental ophthalmology, 2014.
Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related macular degeneration. Ophthalmology, 2014, 121(1): 188-192.
Broadhead G and Chang AA. Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy. Korean J Ophthalmol 2014;28(2):189-191.
Broadhead G, Hong T, Chang AA. Treating the Untreatable Patient: Current Options for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. Acta Ophthalmologica 2014; 92(8):713-23.
Vote B, Chang A, Bourke R. Intravitreal injections: a review of the evidence for best practice: Comment. Letter to the editor. Clinical and Experimental Ophthalmology. 2014; 42(1) p 96-98.
Broadhead G, Grigg J, Chang A, McCluskey P. Efficacy and Safety of Saffron Supplementation: Current Clinical Findings. Critical Reviews in Food Science and Nutrition.
Rush R, Simunovic M, Sheth S, Chang A Hunyor A. 23-Gauge Pars Plana Vitrectomy Versus Scleral Buckling Versus Combined Pars Plana Vitrectomy–Scleral Buckling for Medium-Complexity Retinal Detachment Repair. Asia-Pacific Journal of Ophthalmology: July/August 2014 – Volume 3 – Issue 4 – p 215-219
Chang A. Retina tear and detachment. The need for early diagnosis. Medicine Today January 2014, volume 15, number 1.
Chui J, Herkes G, Chang A. Management of fingolimod associated macular edema, JAMA Ophthalmology. 2013. 131(5) p 694-6
Broadhead G and Chang A. Choroidal Neovascularisation in Acquired Partial Lipodystrophy. European journal Ophthalmology 2013; 23(3): p. 439-41
Wang YD and Chang A. Clinical features and PDT effect of patients with CCSC. International Eye Science. 13:3. 522-526 January 2013
Chang A. Editorial. Is there one less hurdle for patients undergoing macular hole surgery? Asia-Pacific Journal of Ophthalmology. 2(1):1-2, February 2013.
Broadhead, GK, Chang, AA, and McCluskey, P, Genetics in Age-Related Macular Degeneration: Current Research and Implications for Future Treatment, Asia Pacific Journal Ophthalmology, 2012; 1(5): p. 312-18